ATE347103T1 - Reinigung von antigenspezifischen t-zellen - Google Patents
Reinigung von antigenspezifischen t-zellenInfo
- Publication number
- ATE347103T1 ATE347103T1 AT97936461T AT97936461T ATE347103T1 AT E347103 T1 ATE347103 T1 AT E347103T1 AT 97936461 T AT97936461 T AT 97936461T AT 97936461 T AT97936461 T AT 97936461T AT E347103 T1 ATE347103 T1 AT E347103T1
- Authority
- AT
- Austria
- Prior art keywords
- cells
- sup
- specific
- purify
- antigen
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 9
- 238000000746 purification Methods 0.000 title 1
- 238000000034 method Methods 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 102000043129 MHC class I family Human genes 0.000 abstract 2
- 108091054437 MHC class I family Proteins 0.000 abstract 2
- 241000699670 Mus sp. Species 0.000 abstract 2
- 108091008874 T cell receptors Proteins 0.000 abstract 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 239000011324 bead Substances 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 238000000338 in vitro Methods 0.000 abstract 2
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 238000002659 cell therapy Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 230000009261 transgenic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ecology (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2558896P | 1996-09-06 | 1996-09-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE347103T1 true ATE347103T1 (de) | 2006-12-15 |
Family
ID=21826936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT97936461T ATE347103T1 (de) | 1996-09-06 | 1997-08-12 | Reinigung von antigenspezifischen t-zellen |
Country Status (11)
Country | Link |
---|---|
US (2) | US7125964B2 (de) |
EP (1) | EP0937251B1 (de) |
JP (1) | JP4117031B2 (de) |
AT (1) | ATE347103T1 (de) |
AU (1) | AU727541B2 (de) |
CA (1) | CA2264925C (de) |
DE (1) | DE69737028T2 (de) |
DK (1) | DK0937251T3 (de) |
ES (1) | ES2277358T3 (de) |
PT (1) | PT937251E (de) |
WO (1) | WO1998010284A1 (de) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6458354B1 (en) | 1996-03-28 | 2002-10-01 | The Johns Hopkins University | Molecular complexes which modify immune responses |
EP0889964A1 (de) | 1996-03-28 | 1999-01-13 | The Johns Hopkins University | Lösliche divalente und multivalente heterodimäre proteinanalogen |
DE19710496A1 (de) * | 1997-03-13 | 1998-09-17 | Boehringer Mannheim Gmbh | Verfahren zum Nachweis antigenspezifischer T-Zellen nach Anreicherung von mononukleären Zellpopulationen |
US6268411B1 (en) | 1997-09-11 | 2001-07-31 | The Johns Hopkins University | Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses |
CA2370557C (en) * | 1999-04-16 | 2007-12-04 | Zeling Cai | Enriched antigen-specific t-cells, and related therapeutic and prophylactic compositions and methods |
US8609436B2 (en) | 2000-03-17 | 2013-12-17 | Guy's & St Thomas' Hospital NHS Trust (“GST”) | Method |
US8088586B2 (en) * | 2000-03-17 | 2012-01-03 | Oxford Radcliffe Hospital Nhs Trust | Method of producing a body fluid sample depleted of anti-MHC antibodies |
US20040115216A1 (en) * | 2002-07-12 | 2004-06-17 | The Johns Hopkins University | Reagents and methods for engaging unique clonotypic lymphocyte receptors |
DE60234435D1 (de) * | 2002-07-23 | 2009-12-31 | Guy S & St Thomas Hospital Nhs | Methode zum Entfernen von MHC Antikörpern |
WO2004051266A1 (ja) * | 2002-11-14 | 2004-06-17 | Atsushi Muraguchi | 抗原特異的リンパ球検出用マイクロウェルアレイチップ、抗原特異的リンパ球の検出法及び製造方法、並びに抗原特異的リンパ球抗原受容体遺伝子のクローニング方法 |
WO2006026746A2 (en) * | 2004-08-31 | 2006-03-09 | The Government Of United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods to separate and expand antigen-specific t cells |
WO2007035633A2 (en) | 2005-09-16 | 2007-03-29 | President & Fellows Of Harvard College | Screening assays and methods |
AU2007307206B2 (en) | 2006-10-04 | 2016-02-11 | Janssen Pharmaceutica, N.V. | Preparation of inactivated artificial antigen presenting cells and their use in cell therapies |
US20090062237A1 (en) * | 2007-06-15 | 2009-03-05 | Mayo Foundation For Medical Education And Research | Evaluating immune competence |
JP4148367B1 (ja) | 2007-08-02 | 2008-09-10 | 富山県 | 細胞のスクリーニング方法 |
EP2229441B1 (de) | 2007-12-12 | 2014-10-01 | The Board of Trustees of The Leland Stanford Junior University | Verfahren und vorrichtung zur magnetischen trennung von zellen |
KR101384142B1 (ko) * | 2007-12-28 | 2014-04-14 | 삼성디스플레이 주식회사 | 표시기판, 이의 제조방법 및 이를 갖는 표시장치 |
CN104195227B (zh) | 2008-11-07 | 2017-04-12 | 适应生物技术公司 | 通过序列分析监测状况的方法 |
US9506119B2 (en) | 2008-11-07 | 2016-11-29 | Adaptive Biotechnologies Corp. | Method of sequence determination using sequence tags |
US9365901B2 (en) | 2008-11-07 | 2016-06-14 | Adaptive Biotechnologies Corp. | Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia |
US8628927B2 (en) | 2008-11-07 | 2014-01-14 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
US9528160B2 (en) | 2008-11-07 | 2016-12-27 | Adaptive Biotechnolgies Corp. | Rare clonotypes and uses thereof |
US8691510B2 (en) * | 2008-11-07 | 2014-04-08 | Sequenta, Inc. | Sequence analysis of complex amplicons |
US8748103B2 (en) | 2008-11-07 | 2014-06-10 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
DK3059337T3 (da) | 2009-01-15 | 2019-07-22 | Adaptive Biotechnologies Corp | Adaptive immunity profiling og metoder til frembringelse af monoklonale antibodier |
CN102459643B (zh) | 2009-06-25 | 2016-06-01 | 弗雷德哈钦森癌症研究中心 | 检测获得性免疫的方法 |
US9043160B1 (en) | 2009-11-09 | 2015-05-26 | Sequenta, Inc. | Method of determining clonotypes and clonotype profiles |
EP3456847A1 (de) | 2010-05-06 | 2019-03-20 | Adaptive Biotechnologies Corporation | Überwachung von transplantabstossungen mithilfe von klonotyp-profilen |
US10385475B2 (en) | 2011-09-12 | 2019-08-20 | Adaptive Biotechnologies Corp. | Random array sequencing of low-complexity libraries |
EP2768982A4 (de) | 2011-10-21 | 2015-06-03 | Adaptive Biotechnologies Corp | Quantifizierung von adaptiven immunzellgenomen in einer komplexen mischung von zellen |
ES2683037T3 (es) | 2011-12-09 | 2018-09-24 | Adaptive Biotechnologies Corporation | Diagnóstico de tumores malignos linfoides y detección de enfermedad residual mínima |
US9499865B2 (en) | 2011-12-13 | 2016-11-22 | Adaptive Biotechnologies Corp. | Detection and measurement of tissue-infiltrating lymphocytes |
JP6302847B2 (ja) | 2012-03-05 | 2018-03-28 | アダプティヴ バイオテクノロジーズ コーポレーション | 頻度が一致したサブユニットからの、対をなす免疫受容体鎖の決定 |
US9150905B2 (en) | 2012-05-08 | 2015-10-06 | Adaptive Biotechnologies Corporation | Compositions and method for measuring and calibrating amplification bias in multiplexed PCR reactions |
US20160002731A1 (en) | 2012-10-01 | 2016-01-07 | Adaptive Biotechnologies Corporation | Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization |
EP2956481B1 (de) | 2013-02-15 | 2020-07-01 | The Johns Hopkins University | Antigenspezifische t-zell-umleiter |
CA2906076A1 (en) | 2013-03-15 | 2014-09-18 | Abvitro, Inc. | Single cell bar-coding for antibody discovery |
US9708657B2 (en) | 2013-07-01 | 2017-07-18 | Adaptive Biotechnologies Corp. | Method for generating clonotype profiles using sequence tags |
WO2015134787A2 (en) | 2014-03-05 | 2015-09-11 | Adaptive Biotechnologies Corporation | Methods using randomer-containing synthetic molecules |
US10066265B2 (en) | 2014-04-01 | 2018-09-04 | Adaptive Biotechnologies Corp. | Determining antigen-specific t-cells |
EP3132059B1 (de) | 2014-04-17 | 2020-01-08 | Adaptive Biotechnologies Corporation | Quantifizierung von adaptiven immunzellgenomen in einer komplexen mischung von zellen |
JP6672310B2 (ja) | 2014-09-15 | 2020-03-25 | アブビトロ, エルエルシー | ハイスループットヌクレオチドライブラリーシークエンシング |
CA3017170C (en) * | 2014-09-17 | 2021-03-23 | The Johns Hopkins University | Reagents and methods for identifying, enriching, and/or expanding antigen-specific t cells |
WO2016069886A1 (en) | 2014-10-29 | 2016-05-06 | Adaptive Biotechnologies Corporation | Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from many samples |
US10246701B2 (en) | 2014-11-14 | 2019-04-02 | Adaptive Biotechnologies Corp. | Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture |
AU2015353581A1 (en) | 2014-11-25 | 2017-06-15 | Adaptive Biotechnologies Corporation | Characterization of adaptive immune response to vaccination or infection using immune repertoire sequencing |
ES2858306T3 (es) | 2015-02-24 | 2021-09-30 | Adaptive Biotechnologies Corp | Método para determinar el estado de HLA mediante secuenciación del repertorio inmunitario |
AU2016242967B2 (en) | 2015-04-01 | 2021-07-01 | Adaptive Biotechnologies Corp. | Method of identifying human compatible T cell receptors specific for an antigenic target |
US10294454B2 (en) | 2016-08-24 | 2019-05-21 | General Electric Company | Methods and kits for cell activation |
US10428325B1 (en) | 2016-09-21 | 2019-10-01 | Adaptive Biotechnologies Corporation | Identification of antigen-specific B cell receptors |
TW201834669A (zh) | 2017-03-15 | 2018-10-01 | 美商歐卡生物系統公司 | 用於造血幹細胞移植的組合物及方法 |
DE102017125150B4 (de) | 2017-10-26 | 2019-10-10 | Epiontis Gmbh | Endosialin (CD248) als epigenetischer Marker zur Identifizierung von Immunzellen, insbesondere naïver CD8+ T-Zellen |
US11254980B1 (en) | 2017-11-29 | 2022-02-22 | Adaptive Biotechnologies Corporation | Methods of profiling targeted polynucleotides while mitigating sequencing depth requirements |
DE102018132210A1 (de) * | 2018-12-14 | 2020-06-18 | Jacobs University Bremen Ggmbh | Verfahren und Kit zur Detektion von T-Zellen |
PL238336B1 (pl) * | 2019-08-22 | 2021-08-09 | Gdanski Univ Medyczny | Sposób otrzymywania in vitro antygenowo-specyficznych limfocytów T regulatorowych |
EP4110956A1 (de) | 2020-02-28 | 2023-01-04 | CureVac Netherlands B.V. | Hidden-frame-neoantigene |
WO2023068931A1 (en) | 2021-10-21 | 2023-04-27 | Curevac Netherlands B.V. | Cancer neoantigens |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5045320A (en) * | 1989-03-23 | 1991-09-03 | Medical Biology Institute | Large multivalent immunogen |
US5580756A (en) | 1990-03-26 | 1996-12-03 | Bristol-Myers Squibb Co. | B7Ig fusion protein |
US5583031A (en) | 1992-02-06 | 1996-12-10 | President And Fellows Of Harvard College | Empty major histocompatibility class II heterodimers |
US5314813A (en) | 1992-02-19 | 1994-05-24 | Scripps Research Institute | Drosophila cell lines expressing genes encoding MHC class I antigens and B2-microglobulin and capable of assembling empty complexes and methods of making said cell lines |
CA2069541C (en) * | 1992-05-26 | 2005-02-01 | Cornelis J. M. Melief | Induction of an antigen-specific t-lymphocyte response |
US5595881A (en) | 1994-08-09 | 1997-01-21 | Anergen, Inc. | Method for the detection of antigen presenting cells |
EP0814838B1 (de) | 1995-03-08 | 2003-05-14 | The Scripps Research Institute | Antigen präsentierendes system und aktivierung von t-zellen |
-
1997
- 1997-08-12 PT PT97936461T patent/PT937251E/pt unknown
- 1997-08-12 AT AT97936461T patent/ATE347103T1/de active
- 1997-08-12 DE DE69737028T patent/DE69737028T2/de not_active Expired - Lifetime
- 1997-08-12 WO PCT/US1997/013950 patent/WO1998010284A1/en active IP Right Grant
- 1997-08-12 EP EP97936461A patent/EP0937251B1/de not_active Expired - Lifetime
- 1997-08-12 ES ES97936461T patent/ES2277358T3/es not_active Expired - Lifetime
- 1997-08-12 AU AU39124/97A patent/AU727541B2/en not_active Expired
- 1997-08-12 DK DK97936461T patent/DK0937251T3/da active
- 1997-08-12 JP JP51266098A patent/JP4117031B2/ja not_active Expired - Fee Related
- 1997-08-12 CA CA2264925A patent/CA2264925C/en not_active Expired - Lifetime
-
2004
- 2004-02-23 US US10/785,472 patent/US7125964B2/en not_active Expired - Fee Related
-
2005
- 2005-09-06 US US11/219,967 patent/US20060134125A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ES2277358T3 (es) | 2007-07-01 |
AU727541B2 (en) | 2000-12-14 |
CA2264925A1 (en) | 1998-03-12 |
DE69737028T2 (de) | 2007-06-28 |
JP4117031B2 (ja) | 2008-07-09 |
EP0937251B1 (de) | 2006-11-29 |
EP0937251A1 (de) | 1999-08-25 |
AU3912497A (en) | 1998-03-26 |
DK0937251T3 (da) | 2007-02-19 |
US20060134125A1 (en) | 2006-06-22 |
PT937251E (pt) | 2007-01-31 |
US20040137617A1 (en) | 2004-07-15 |
JP2001504323A (ja) | 2001-04-03 |
DE69737028D1 (de) | 2007-01-11 |
WO1998010284A1 (en) | 1998-03-12 |
US7125964B2 (en) | 2006-10-24 |
CA2264925C (en) | 2010-12-07 |
EP0937251A4 (de) | 2002-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE347103T1 (de) | Reinigung von antigenspezifischen t-zellen | |
Chemin et al. | Effector functions of CD4+ T cells at the site of local autoimmune inflammation—lessons from rheumatoid arthritis | |
Braciale et al. | Simultaneous expression of H-2-restricted and alloreactive recognition by a cloned line of influenza virus-specific cytotoxic T lymphocytes. | |
Carli et al. | Review human Th1 and Th2 cells: functional properties, regulation of development and role in autoimmunity | |
Stanciu et al. | The role of ICAM-1 on T-cells in the pathogenesis of asthma | |
Hutchings et al. | The detection and enumeration of cytokine-secreting cells in mice and man and the clinical application of these assays | |
DK0593754T3 (da) | Peptider fra humant papillomavirus til anvendelse i præparater til induktion af humant T-celle respons | |
ATE79138T1 (de) | Typenspezifische papillomavirus-dns-sequenzen und peptide. | |
DK0643726T3 (da) | Peptider af humant p53-protein til anvendelse i sammensætninger, som inducerer humant T-celle-respons, og humane p53-protei | |
DK1017721T3 (da) | Rekombinante MHC molekyler, der kan anvendes til manipulation af antigenspecifikke T-celler | |
CY1109837T1 (el) | Διαγνωστικο και θεραπευτικο επιτοπιο | |
ATE205537T1 (de) | Verwendung von plasmiden zur herstellung eines impfstoffs bei mensch und tier | |
MX9602495A (es) | Peptidos novedosos derivados de autoantigeno para usarse en inmunoterapia de enfermedades autoinmunes. | |
Moutsopoulos et al. | Immunopathogenesis of sjogren's syndrome:“Facts and fancy” | |
Borhis et al. | B-cell-activating factor and the B-cell compartment in HIV/SIV infection | |
Julius et al. | The molecular interactions with helper T cells which limit antigen‐specific B cell differentiation | |
Guimezanes et al. | A viral peptide can mimic an endogenous peptide for allorecognition of a major histocompatibility complex class I product | |
Tchang et al. | Diverging role for coronin 1 in antiviral CD4+ and CD8+ T cell responses | |
DE59508137D1 (de) | Spezifische bindungssubstanzen für antikörper und deren verwendung für immunoassays oder vakzine | |
Jardieu et al. | Carrier-specific suppression of antibody responses by antigen-specific glycosylation-inhibiting factors. | |
Rigaud et al. | Induction of CIITA and modification of in vivo HLA-DR promoter occupancy in normal thymic epithelial cells treated with IFN-gamma: similarities and distinctions with respect to HLA-DR-constitutive B cells. | |
Malyshkina et al. | Cytotoxic CD4+ T cells in chronic viral infections and cancer | |
JPS6150998A (ja) | ペンタペプチド化合物の製造方法 | |
Schröder et al. | Specificity of monoclonal antibodies to an EBV transformed B-cell line | |
Epton et al. | Solid (gel) phase synthesis of fully-protected acylpeptide hydrazides with hydrazine-labile sidechains |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 0937251 Country of ref document: EP |